In human endometrium, cell proliferation is regulated by ovarian steroids through heterotypic interactions between stromal and epithelial cells populating this tissue. The authors test the proliferative effects of tibolone and its metabolites using endometrial co-cultures that mimic the normal proliferative response to hormones. They found that both the Δ 4 -tibolone metabolite and the pure progestin ORG2058 counteract estradiol-driven epithelial cell proliferation. Surprisingly, the estrogen receptor binding 3hydroxyl-metabolites of tibolone also counteracted estradiol-driven proliferation. Inhibition of proliferation by 3β-OH-tibolone was abrogated by low doses of the progesterone receptor antagonist mifepristone. This suggests that 3β-OH-tibolone is converted to a progestagenic metabolite. The authors found that the stromal cells used in the co-cultures express high levels of the ketosteroid dehydrogenase AKR1C2, which is able to oxidize 3β-OH-tibolone back to tibolone. Thus, the unexpected progestagenic effect of 3β-OH-tibolone in these co-cultures may be due to metabolic activity present in the stromal cells of the co-cultures.
response to hormones, including epithelial-stromal interactions that regulate tissue homeostasis.
The use of primary cell culture systems for physiological studies is difficult to implement systematically because of patient-to-patient variations that impede statistical analysis, and procuring endometrial tissue and generating primary cultures is a costly and time-consuming enterprise. We have previously demonstrated that under our growth conditions, the Ishikawa cells can be substituted for the normal epithelial component. Recently, we described an immortalized endometrial stromal cell line that can be substituted for the normal stromal component in the co-culture. 2 We believe that this co-culture system will be advantageous for the studies of hormonal effects in the endometrium and are currently testing a variety of hormonal analogs.
In the present study, we test the effects of tibolone and its principal metabolites on endometrial proliferation in this co-culture system. Tibolone is a synthetic steroid that is used in many countries for perimenopausal and postmenopausal hormone replacement therapy. A number of clinical studies report that tibolone causes relief of climacteric symptoms and provides benefits to bone health. 3 These effects resembling those of estradiol therapy are in contrast to other studies showing that in breast R egulation of cell proliferation in the endometrium results from complex interactions between the stromal and epithelial compartments, as demonstrated in vivo in the mouse and in vitro using tissue reconstruction. Co-cultures of normal human stromal and epithelial cells have shown that appropriate hormonal responses regulating epithelial cell proliferation depend on the presence of stromal cells or medium conditioned by them. 1 These latter studies point out the role of paracrine growth factors secreted by stromal cells as regulators of epithelial cell proliferation. The benefit of studies in this system, in principle, is that they may allow us to dissect the mechanisms involved in the endometrial tissue, tibolone has no estrogenic/progestagenic effects 4 and that in endometrium, tibolone exerts progestagenic effects. Overall, the pattern of clinical effects induced by tibolone appears to be estrogenic in bone and brain, absent in the breast, and progestagenic in the endometrium.
This differential activity on various target tissues is attributed to the hormone receptor-binding capacities of the metabolites of tibolone. The principal metabolites found in the blood include 3α-and 3β-hydroxy tibolone and, to a lesser extent, Δ 4 -tibolone. 5 In vitro, tibolone itself binds poorly to hormone receptors, while the 3αand 3β-hydroxy (OH) metabolites bind solely to the estradiol receptors with a preference for ERα over ERβ. 6 The Δ 4 -tibolone metabolite binds the progesterone receptor.Thus, the proportions of estrogenic versus progestagenic metabolites formed within a tissue are thought to determine the hormonal effect of tibolone on different steroid responsive tissues.Tibolone has been proposed to belong to a new class of steroid analogs, called selective tissue estradiol activity regulators (STEARs). 7 Interestingly, we found that all the tibolone compounds tested inhibit estradiol-driven proliferation of the epithelial component. We show that the stromal and epithelial cells express the ketosteroid dehydrogenase AKR1C2, which may allow for the conversion of 3β-OH-tibolone back to tibolone. 8 From our observations, using the co-culture system, we conclude that tibolone counteracts estradiol-driven proliferation in the uterus in a manner similar to progestins and that the balance of metabolism of tibolone in the endometrium favors the production of the progestagenic metabolites.
MATERIALS AND METHODS

Reagents and Cell Culture
Tibolone, tibolone metabolites (3α-OH-tibolone, 3β-OH-tibolone, and Δ 4 -tibolone), and progestin ORG2058 were the generous gifts of Organon NV (Oss, the Netherlands). Mifepristone and 17β-estradiol were obtained from Sigma (St Louis, MO). The immortalized normal endometrial stromal cell line SHT290 (SHT) was developed in our laboratory, 2 and the Ishikawa epithelial endometrial adenocarcinoma cell line 9 was obtained from Dr B. Lessey (Greenville Hospital System University Medical Center, Greenville, SC). Both cell lines were maintained in steroid-free medium (designated hereafter as JAC4) consisting of a 1:1 mixture of Ham F12 (GIBCO, Invitrogen Corp, Carlsbad, CA) and M199 basal medium (Sigma) supplemented with 4% charcoalstripped fetal bovine serum (Hyclone, Logan, UT), 0.25% ITS+ (insulin-transferrin-selenium plus lipoic acid; BD Biosciences, Becton Dickinson, Franklin Lakes, NJ), 0.1 mM phosphorylethanolamine (Sigma), and 2 mM glutamine (GIBCO) and antibiotic/antimycotic solution (hereafter referred to as ABAM; GIBCO) diluted to yield 100 U/mL penicillin G sodium, 100 μg/mL streptomycin sulfate, and 250 ng/mL amphotericin B. This medium and all other media were phenol red-free. All cultures described in this report were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
Assessment of Cell Proliferation
Stromal cells grown in JAC4 medium were seeded in 12-well cluster culture plates (BD Biosciences) at 50 000 cells per well.The next day, Ishikawa cells grown in JAC4 were seeded onto cell culture inserts with 0.4-μm porosity (BD Biosciences) at a density of 4000 cells per insert. The inserts were suspended above the adherent stromal cells so that they were covered by the culture medium.To assess proliferation, Ishikawa cells were detached from the inserts using a 1:1 mixture of versene (GIBCO) and trypsin-EDTA, thoroughly mixed to obtain single-cell suspensions, and enumerated with a Coulter Counter (Beckman Coulter Inc, Fullerton, CA).
To conduct the assay for measuring estrogenic activity assays, stromal cells were mixed with 0.4 mL of growth factor-reduced, phenol red-free Matrigel (BD Biosciences), as previously described. 10 Co-cultures were equilibrated in steroid-free JAC4 for 48 hours prior to the addition of 10 -8 M 17β-estradiol or tibolone metabolites.The cultures were subsequently treated with appropriate hormones in JAC4 for a period of 48 hours and switched to a serum-free medium (formulated as F12/M199 mixture, 0.25% ITS+, 0.25% bovine serum albumin [Sigma], 20 ng/mL epidermal growth factor [BD Biosciences], ABAM, 2 mM glutamine) containing the same hormones for an additional 64 hours, after which the Ishikawa cells were counted.
To conduct assays for measuring progestagenic activity, co-cultures were equilibrated in JAC4 supplemented with 10 -8 M 17β-estradiol for 48 hours, after which the medium was changed to JAC4 supplemented with a combination of estradiol 10 -8 M and 5 × 10 -7 M of 1 of the tibolone metabolites or 10 -8 M estradiol plus 10 -7 M of the pure progestin ORG2058 for 48 hours. After 48 hours, the cultures were switched to the serum-free medium described above supplemented with estradiol and added compounds for an additional 64 hours, after which the Ishikawa cells were counted.Assays to evaluate tibolone did not include 10 -8 M estradiol because tibolone is assumed to be converted to a mixture of estrogenic and progestagenic metabolites. 11 Control cultures used for the assay of progestagenic activity were treated with 10 -8 M 17β-estradiol for the duration of the experiment.
Statistical Analysis
Each treatment was performed on a total of 6 co-cultures per experiment, and the mean and standard deviation were calculated. A Student t test was applied to ascertain the significance (P < .05) of differences in cell numbers between treatments. Each experiment was repeated at least twice.
Detection of AKR1C Message by Reverse-Transcriptase Polymerase Chain Reaction
Total RNA was prepared from cultured endometrial cells using an RNA purification kit from Promega (Madison, WI). Reverse transcription was performed using AMV reverse transcriptase according to the manufacturer's instructions (Roche, Indianapolis, IN) in the presence of random hexamers (GIBCO). Polymerase chain reaction (PCR) reaction products were loaded on a 2% agarose gel and electrophoresed in parallel to a DNA ladder standard. Subsequently, the gel was stained with ethidium bromide. For negative controls, cDNA was replaced by water, and the absence of genomic DNA in the RNA samples was verified by showing that direct PCR amplification of the RNA samples without a reverse-transcription step did not yield any product. All PCR products were normalized to the PCR product of hypoxanthine phosphoribosyl transferase 1 (Lesch-Nyhan syndrome; HPRT1), which is unresponsive to variations of hormones. Primers for the amplification of HPRT1 were designed in house. The sequences of the primers for amplification of AKR1C2 and 3 were as described by Penning et al. 12 
RESULTS
Validation of the Co-culture System With Estradiol
We determined that, when grown alone, neither the stromal cells nor the Ishikawa cells used in the co-culture system responded to estradiol by an increase in proliferation (data not shown). Having previously demonstrated that in cocultures normal stromal cells regulate the estrogenic proliferative response of Ishikawa cells, 1 we confirmed that co-culture of Ishikawa cells with the recently established immortalized normal stromal cell line SHT290 18 also shows a significant effect of estradiol on the proliferation of Ishikawa cells ( Figure 1 ).As described in the Materials and Methods section, the assay for estrogenic activity is conducted over a period of 7 days (156 hours), during which the medium is changed every other day. If instead of renewing the medium every other day ( Figure 1A) we renew the medium every day ( Figure 1B) , the proliferation of the Ishikawa cells in response to estradiol is greatly diminished, suggesting that preventing the accumulation of growth factors in the medium adversely affects the proliferative response of the Ishikawa cells induced by estradiol.
Proliferation of Ishikawa Cells in the Presence of Tibolone and Its Metabolites
The tibolone metabolites were tested along with estradiol employing the co-culture assay used previously to assess estradiol-induced cell proliferation.As shown in Figure 2A , while estradiol treatment gave a significant stimulation of Ishikawa cell growth, the 3α-OH-tibolone and 3β-OHtibolone derivatives did not stimulate the proliferation of Ishikawa cells significantly. Notably, the 3-OH-tibolone derivatives were used at concentrations 50 times higher than estradiol; at these concentrations, one may expect a similar receptor activation. 6 Using the assay for estrogenic activity, we did not observe an effect on proliferation with Δ4-tibolone, the pure progestin ORG2058 ( Figure 2B ), or tibolone (not shown).Thus, none of the tibolone metabolites induced an estrogenic effect ( Figure 2 ).
To determine whether these compounds exerted a progestagenic affect, the tibolone metabolites' ability to inhibit estrogen-mediated proliferation was tested. In the progestagenic assay, the co-culture is primed with estradiol for 2 days to ensure a high expression of progesterone receptors, after which the medium is renewed with a combination of estradiol, with the test progestagenic compound as described in the Materials and Methods section. These studies showed that like the progestin ORG2058, Δ 4tibolone counteracts the proliferative effect of estradiol ( Figure 3 ). Curiously, the 3-OH-tibolone metabolites also had an inhibitory effect, but this effect was not as strong as either ORG2058 or Δ 4 -tibolone.
To confirm that the inhibition of estradiol-driven proliferation was mediated by the progesterone receptor, we tested whether the effect of tibolone and its metabolites could be inhibited by inclusion of the progesterone receptor antagonist mifepristone. In studies in vitro, it has been shown that in the endometrium, tibolone is mainly converted to the Δ 4 -and the 3β-OH metabolites 11 ; therefore, we tested only these 2 metabolites. Mifepristone at a concentration of 10 -7 M largely antagonizes the effect of Δ 4 -tibolone, but it did not influence the effect of 3β-OH-tibolone. Since mifepristone may express agonistic activity in our system, we performed a dose-response study, titrating different concentrations of mifepristone versus a constant dose of 3β-OH-tibolone. Figure 4B shows that lower concentrations of mifepristone can indeed counteract the progestagenic effects of 3β-OH tibolone on estradiol-driven proliferation.
Expression of AKR1C Enzymes in Cultures
One explanation for the unexpected progestagenic effect of the 3β-OH-metabolite could be the conversion of the 3β-OH-metabolite to tibolone and further to the Δ 4 -isomer in the co-culture system. Recently, it has been shown that the ketosteroid dehydrogenase enzymes of the AKR1C family are capable of metabolizing the 3-OHtibolone metabolites. 8 Although AKR1C1, AKR1C3, and AKR1C4 act as reductases, the AKR1C2 enzyme is capable of oxidizing the 3β-OH-tibolone metabolite back to tibolone. Using reverse-transcriptase PCR, we demonstrated that in the presence of estradiol, both the AKR1C3 and AKR1C2 messenger RNAs are expressed by the Ishikawa cells and the stromal cells, raising the possibility that when expressed, their activity influences the fate of steroids added to the co-culture ( Figure 5 ). The presence of these enzymes and the observation that a low concentration of mifepristone can block the effect of 3β-OH-tibolone together may explain the paradoxical progestagenic effects of 3-OH-metabolite of tibolone in the co-culture.
DISCUSSION
The Ishikawa endometrial adenocarcinoma cell line is widely used to evaluate the properties of human endometrial epithelium. We have shown previously that these cells recapitulate the epithelial responses to estradiols and progestins more accurately when they are co-cultured with human endometrial stromal cells. Previous findings indicated that the proliferative response induced by estradiol in the epithelial cells resulted from the secretion of paracrine factors by the estradiol-stimulated stromal cells. 1, 13 In the current study, the experiment presented in Figure 1 shows that secreted factors must accumulate over time to fully exert their regulatory effects on the proliferation of the epithelial component in the co-culture system.This effect demonstrates the determining role of the stromal cells in regulating the growth of epithelial cells. The co-culture system allows testing of the progestagenic or estrogenic activities of compounds. It should be useful to dissect the complex effects of many hormone analogs on endometrial growth. Tibolone, a hormone replacement therapy drug that has been extensively studied in clinics, was an appropriate test compound because it exerts differential effects on estrogen target tissues, depending on the local concentration of its various metabolites as well as the ability of tissue enzymes to inactivate or store the metabolites through sulfation/desulfation.
In the endometrium, the overall long-term effect of tibolone is progestagenic. Histological studies following treatment with tibolone for 3 months or longer revealed that the endometrium becomes atrophic, suggesting a progestagenic inhibition or lack of estrogenic stimulation of endometrial cell proliferation. 14, 15 In the laboratory, the progestagenic effects of tibolone on the endometrium have been demonstrated by measuring various progesterone-regulated factors. Early studies using cultures of fragments of endometrial tissue demonstrated that similar to progesterone, tibolone and Δ 4 -tibolone counteracted the effect of estradiol on the production of prostaglandin PGF 2α . 16 Recent studies performed in vitro using normal endometrial stromal cells exposed to tibolone and its metabolites have demonstrated the expression of end points indicative of progesterone predominance. [17] [18] [19] Analysis of gene expression profiles by microarray analysis of cell lines reveals that tibolone has a profile similar but not identical to that of the progestagen medroxyprogesterone acetate. 20 In our present study, tibolone and all its metabolites were found to be inactive when tested for estrogenic activity, measured by the stimulation of endometrial epithelial cell proliferation. In the protocol for progestagenic activity, tibolone metabolites were able to counteract the proliferation of Ishikawa cells that is induced by estradiol; this demonstrates their progestagenic activity. Thus, the co-culture system appears to closely mimic the effect of tibolone in vivo. The progestagenic effects of tibolone and of the Δ 4 -metabolite had been expected because tibolone is converted to its Δ 4 -isomer in the endometrium, and Δ 4 -tibolone has been shown to bind the progesterone receptor. In contrast, the activity of the 3-OH-tibolone metabolites as progestins was surprising, as these metabolites are known to bind the estradiol receptors, not the progesterone receptor. 6 We next attempted to determine whether the progesterone receptor was involved in the abrogation of estradioldriven proliferation. To do this, we conducted the progestagenic assay in the presence of the progesterone receptor antagonist mifepristone. The effect of the Δ 4 -isomer on estradiol-driven proliferation could be counteracted by 10 -7 M mifepristone. Lower concentrations of mifepristone suffice to abrogate the progestagenic activity detected in 3β-OH-tibolone-treated culture ( Figure 4B) . A smaller amount of progestagenic compounds is generated in the 3β-OH-tibolone-treated cultures, and therefore, lower concentrations of mifepristone are needed to counteract the effect of 3β-OH-tibolone. Higher concentrations of mifepristone are not efficacious, perhaps because mifepristone has some intrinsic progestagenic agonist activity that may override its antiprogestagenic effects, as has been shown in other systems. 21 To explain how 3β-OH-tibolone could be metabolized in the co-culture system, we examine the expression of the AKR1C enzymes. It had been shown previously that the ketosteroid dehydrogenase AKR1C2 can oxidize 3β-OH-tibolone back to tibolone in vitro. 8 We attempted to confirm this hypothesis using the ketosteroid dehydrogenases inhibitors flufenamic acid 8 and cholanic acid. Unfortunately, flufenamic acid reduced the estradioldriven increase in proliferation (perhaps because of its known effects on prostaglandin levels). 22 Studies with cholanic acid also were unsuccessful because of solubility problems. Cholanic acid could not be used at the concentration shown to inhibit AKR1C2 in vitro 23 without increasing the vehicle volume to an unacceptable percentage (data not shown).AKR1C-2 and -3 were expressed at higher levels in the stromal cells than in the Ishikawa epithelial cells. Because it is not clear whether expression of those metabolic enzymes are under the control of steroid hormones, this issue merits further investigation.
CONCLUSION
Our results demonstrate the importance of the use of the co-culture model to study the regulation of cell proliferation in human endometrium. Applying this system to the study of tibolone, we find that tibolone and its metabolites exert no estrogenic proliferative effects. In contrast, perhaps because of stromal metabolism, all tibolone compounds demonstrate progestagenic activity. These results are in agreement with clinical observations of an atrophic endometrium, indicative of an overall progestagenic effect.
